Enoxaparin in Primary Angioplasty: In-Hospital and one Month Results of a Pilot Study

摘要

Enoxaparin has provided excellent results in the treatment of non Q wave infarction and unstable angina. Besides, it has proven its efficacy and safety as anticoagulant agent during programmed percutaneous interventions. The aim of our work is to confirm the feasibility and safety of enoxaparin as anticoagulant agent during primary PTCA. We performed 21 consecutive procedures in patients referred for acute MI (13 males (61.9%); aged 65 +- 12 years),using a dose of 0.75 mg/kg of enoxaparin during PTCA. During in-hospital follow up one patient died; no major haemorrhages occurred. At 1 month follow-up there was one sudden death; no new ischaemic event and no need for re-intervention. In conclusion, the use of enoxaparin routinely in primary PTCA has a security profile similar to that of unfractionated heparin.